title: Nanomedicine and nanotoxicology: the pros and cons for neurodegeneration and brain cancer.
abstract: Current strategies for brain diseases are mostly symptomatic and noncurative. Nanotechnology has the potential to facilitate the transport of drugs across the blood-brain barrier and to enhance their pharmacokinetic profile. However, to reach clinical application, an understanding of nanoneurotoxicity in terms of oxidative stress and inflammation is required. Emerging evidence has also shown that nanoparticles have the ability to alter autophagy, which can induce inflammation and oxidative stress, or vice versa. These effects may increase neurodegenerative processes damage, but on the other hand, they may have benefits for brain cancer therapies. In this review, we emphasize how nanomaterials may induce neurotoxic effects focusing on neurodegeneration, and how these effects could be exploited toward brain cancer treatment.
authors.affiliation: Department of Pharmaceutical Science & Technology, School of Chemical & Pharmaceutical Sciences, University of Chile, Santiago 8380494, Chile.|Laboratory of Neuroplasticity & Neurogenetics, School of Chemical & Pharmaceutical Sciences, University of Chile, Santiago 8380494, Chile.
authors.forename: Johanna
authors.initials: J
authors.lastname: Catalan-Figueroa
authors.affiliation: Advanced Center for Chronic Diseases (ACCDiS), Santiago 8380494, Chile.
authors.forename: Sujey
authors.initials: S
authors.lastname: Palma-Florez
authors.affiliation: Department of Pharmaceutical Science & Technology, School of Chemical & Pharmaceutical Sciences, University of Chile, Santiago 8380494, Chile.
authors.forename: Gonzalo
authors.initials: G
authors.lastname: Alvarez
authors.affiliation: Department of Pharmaceutical Science & Technology, School of Chemical & Pharmaceutical Sciences, University of Chile, Santiago 8380494, Chile.
authors.forename: Hans F
authors.initials: HF
authors.lastname: Fritz
authors.affiliation: Department of Pharmaceutical Science & Technology, School of Chemical & Pharmaceutical Sciences, University of Chile, Santiago 8380494, Chile.
authors.forename: Miguel O
authors.initials: MO
authors.lastname: Jara
authors.affiliation: Department of Pharmaceutical Science & Technology, School of Chemical & Pharmaceutical Sciences, University of Chile, Santiago 8380494, Chile.|Advanced Center for Chronic Diseases (ACCDiS), Santiago 8380494, Chile.
authors.forename: Javier O
authors.initials: JO
authors.lastname: Morales
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001932:Brain Neoplasms / Q000188:drug therapy*; D015195:Drug Design; D006801:Humans; D053769:Nanocapsules / Q000008:administration & dosage* / Q000009:adverse effects*; D050997:Nanomedicine / Q000639:trends; D019636:Neurodegenerative Diseases / Q000139:chemically induced* / Q000517:prevention & control*; D018570:Risk Assessment; D014116:Toxicology / Q000639:trends
chemical_list: D000970:Antineoplastic Agents; D053769:Nanocapsules
keywords: autophagy; brain; cancer; drug delivery; nanomedicine; nanotoxicology; neurodegeneration; oxidative stress